You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Pharma & Healthcare

Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Research Report 2021 Professional Edition

Market Analysis and Insights: Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
The research report studies the Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market size is projected to reach US$ 545.1 million by 2027, from US$ 433.5 million in 2020, at a CAGR of 3.3% during 2021-2027.
Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Scope and Segment
The global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Corticosteroids
Intravenous Immunoglobulin (IVIG)
Anti-D Immunoglobulin
Thrombopoietin Receptor Agonists (TPO-RA)
Others
by Application, this report covers the following segments
Hospitals
Clinics
Others
Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics key players in this market include:
Roch
Amgen Inc
Grifols Biologicals Inc.
GlaxoSmithKline Plc
1 Market Overview of Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics
1.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Overview
1.1.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Scope
1.1.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Status and Outlook
1.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2016-2027)
1.4 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Historic Market Size by Region (2016-2021)
1.5 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2016-2027)
1.6.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2016-2027)
1.6.2 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2016-2027)
1.6.3 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2016-2027)
1.6.4 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2016-2027)
1.6.5 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size (2016-2027)

2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Overview by Type
2.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Historic Market Size by Type (2016-2021)
2.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecasted Market Size by Type (2022-2027)
2.4 Corticosteroids
2.5 Intravenous Immunoglobulin (IVIG)
2.6 Anti-D Immunoglobulin
2.7 Thrombopoietin Receptor Agonists (TPO-RA)
2.8 Others

3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Overview by Application
3.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Historic Market Size by Application (2016-2021)
3.3 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Forecasted Market Size by Application (2022-2027)
3.4 Hospitals
3.5 Clinics
3.6 Others

4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Competition Analysis by Players
4.1 Global Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics as of 2020)
4.3 Date of Key Players Enter into Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market
4.4 Global Top Players Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Headquarters and Area Served
4.5 Key Players Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans

5 Company (Top Players) Profiles and Key Data
5.1 Roch
5.1.1 Roch Profile
5.1.2 Roch Main Business
5.1.3 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products, Services and Solutions
5.1.4 Roch Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) & (2016-2021)
5.1.5 Roch Recent Developments
5.2 Amgen Inc
5.2.1 Amgen Inc Profile
5.2.2 Amgen Inc Main Business
5.2.3 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products, Services and Solutions
5.2.4 Amgen Inc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) & (2016-2021)
5.2.5 Amgen Inc Recent Developments
5.3 Grifols Biologicals Inc.
5.3.1 Grifols Biologicals Inc. Profile
5.3.2 Grifols Biologicals Inc. Main Business
5.3.3 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products, Services and Solutions
5.3.4 Grifols Biologicals Inc. Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) & (2016-2021)
5.3.5 GlaxoSmithKline Plc Recent Developments
5.4 GlaxoSmithKline Plc
5.4.1 GlaxoSmithKline Plc Profile
5.4.2 GlaxoSmithKline Plc Main Business
5.4.3 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Products, Services and Solutions
5.4.4 GlaxoSmithKline Plc Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Revenue (US$ Million) & (2016-2021)
5.4.5 GlaxoSmithKline Plc Recent Developments

6 North America
6.1 North America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2016-2027)
6.2 United States
6.3 Canada

7 Europe
7.1 Europe Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe

8 Asia-Pacific
8.1 Asia-Pacific Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific

9 Latin America
9.1 Latin America Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America

10 Middle East & Africa
10.1 Middle East & Africa Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa

11 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Dynamics
11.1 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Industry Trends
11.2 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Drivers
11.3 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Challenges
11.4 Idiopathic Thrombocytopenic Purpura (ITP) Therapeutics Market Restraints

12 Research Finding /Conclusion

13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • FORMAT: PDF
  • PUBLISHED DATE: Jun, 2021
  • NO OF PAGES: 140